Skip to main content
Premium Trial:

Request an Annual Quote

Compendia Nabs $2.4M SBIR Grant for Oncomine Professional Project; Co-Founder Named CEO

NEW YORK (GenomeWeb News) — Compendia Bioscience yesterday said it has won a $2.4-million SBIR Fast Track Award from the National Cancer Institute to help it further develop its Oncomine Professional technology.
 
Oncomine, designed for biomarker and therapeutic target discovery, validation, and prioritization, combines more than 20,000 cancer transcriptome profiles with an analysis engine and a web application to mine and visualize data, Compendia said.
 
The money for the project, called "Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development,” also results in Compendia co-founder Dan Rhodes being named CEO of the company. He will also serve as the principal investigator for the project.
 
Current CEO John Freshley will remain with the company as chief business officer overseeing sales, marketing, and corporate development, Compendia said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.